MedX Health Evaluating Options for $1M Financing
$1,000,000 Dollar Growth Financing to Accelerate the Global Expansion of MoleMate Skin Cancer Imaging Sales and Marketing Programs
MISSISSAUGA, ON, May 22, 2012 /CNW/ - MedX Health Corp., (TSXV.MDX) with worldwide revenues in drug free, non-invasive low level laser light therapy and light imaging systems, announced today that they are withdrawing the original private placement announced on April 2, 2012 and evaluating a number of financing vehicles to raise up to $1,000,000 to accelerate the expansion of the MoleMate skin cancer imaging sales and marketing programs.
"This growth financing will allow MedX to deploy the capital needed to further accelerate our sales and marketing programs in North America, Europe, Australia, and entry into new geographies. As the leading innovator in this emerging market space, this funding will go a long way in helping us share the company's vision of becoming the premier provider of a better way to identify skin cancer early, without a surgical biopsy, and will give us the ability to immediately implement our ambitious growth plans," said Steve Guillen, President & CEO.
The website www.simsys-molemate.com contains additional information on MoleMate and SIMSYS, including information on the technology behind these products, as well as product demos, and information on how other physicians have integrated the skin cancer imaging system into their practice.
About MedX Health Corp.
MedX is a twelve (12) year old Canadian company, headquartered in Mississauga, Ontario (Toronto), and is a global leader in the design, manufacturing and distribution of quality low level laser and light therapy technologies for use in numerous medical settings, including rehab/chiropractic, dental, wound care, and veterinary medicine, providing patients with drug free and non-invasive treatment of tissue damage and pain. MedX laser and light products are FDA approved, Health Canada cleared, and CE Mark approved for use in North America as well as the European Union. MedX acquired the worldwide assets related to MoleMate for the early detection of skin cancer in June 2011.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
For further information:
President and Chief Executive Officer
MedX Health Corp. email@example.com
Phone: (905) 670-4428